Trial Profile
PARABO - Pain Evaluation in Radium-223 (Xofigo) Treated mCRPC Patients With Bone Metastases - a Non-interventional Study in Nuclear Medicine Centers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms PARABO
- Sponsors Bayer
- 22 Jul 2020 Status changed from active, no longer recruiting to completed.
- 24 May 2020 Planned primary completion date changed from 30 Apr 2020 to 31 May 2020.
- 29 Mar 2020 Planned End Date changed from 30 Sep 2023 to 15 Jul 2020.